William B. Hurlbut, MD, is Adjunct Professor and Senior Research Scholar in Neurobiology at the Stanford Medical School. After receiving his undergraduate and medical training at Stanford University, he completed postdoctoral studies in theology and medical ethics, studying with Robert Hamerton-Kelly, the Dean of the Chapel at Stanford, and subsequently with the Rev. Louis Bouyer of the Institut Catholique de Paris.
His primary areas of interest involve the ethical issues associated with advancing biomedical technology, the biological basis of moral awareness, and studies in the integration of theology with the philosophy of biology. He is the author of numerous publications on science and ethics including the co-edited volume Altruism and Altruistic Love: Science, Philosophy, and Religion in Dialogue (2002, Oxford University Press), and “Science, Religion and the Human Spirit” in the Oxford Handbook of Religion and Science (2008). He was also co-chair of two interdisciplinary faculty projects at Stanford University, “Becoming Human: The Evolutionary Origins of Spiritual, Religious, and Moral Awareness” and “Brain, Mind, and Emergence.”
In addition to teaching at Stanford, he has also worked with NASA on projects in astrobiology and was a member of the Chemical and Biological Warfare Working group at the Center for International Security and Cooperation. From 2002-2009 Dr. Hurlbut served on the President’s Council on Bioethics. He is the author of “Altered Nuclear Transfer” (2005, Stem Cell Reviews) a proposed technological solution to the moral controversy over embryonic stem cell research.
Dr. Hurlbut serves as a Steering Committee Member of the Templeton Religion Trust.
Academic Staff - Hourly - CSL, Neurobiology Department
MD, Stanford University Medical School (1974)
BS, Stanford University, Biology (1968)
Current Research and Scholarly Interests
Stem Cell Ethics
Ethics and embryonic stem cell research - Altered nuclear transfer as a way forward
2007; 21 (2): 79-83
Ethical controversy in stem cell research arises because current methods to produce embryonic stem cell lines require the destruction of living human embryos. For this reason, there is increasing interest in developing alternative, non-embryonic sources of pluripotent stem cells. This effort is especially important in the US due to the prevailing policy against federal funding of embryo-destructive research. Altered nuclear transfer (ANT) is one of several potential methods to develop alternative sources of pluripotent stem cells. This approach employs the technique of somatic cell nuclear transfer, but the somatic cell nucleus or egg cytoplasm (or both) are first altered before the somatic cell nucleus is transferred into the oocyte. This alteration precludes the coordinated organization and developmental potential that is necessary for the resulting biological entity to be an embryo, but it still allows the entity to generate pluripotent stem cells. Proof-of-principle for one variant of ANT has been established in mice by silencing the functional expression of the gene Cdx2 in the somatic cell nucleus prior to its transfer into an enucleated egg. From the resulting non-embryonic laboratory construct, fully functional pluripotent stem cells were procured. Other more recent studies have suggested the possibility of achieving the same results by preemptively silencing maternally derived Cdx2 messenger RNA in the egg before the act of nuclear transfer. The procedure would produce the equivalent of a tissue culture of pluripotent stem cells. In contrast to the use of embryos 'left over' from clinical in vitro fertilization, ANT could produce pluripotent stem cell lines with an unlimited range of specifically selected and controlled genotypes. Such flexibility would greatly facilitate the study of disease, drug development, and toxicology testing, and may allow the production of therapeutically useful pluripotent stem cells that are immune-compatible. If developed to the point of scientific reliability, ANT would be a valuable research tool for the study of other aspects of cell development and differentiation, including gene expression patterns, imprinting, and cell-cell signaling. ANT would also help to clarify definitions and boundaries that distinguish true organisms from 'biological artifacts' and, thereby, provide moral precedent to guide future progress in developmental biology.
View details for Web of Science ID 000246260200003
View details for PubMedID 17402791
Science, religion, and the politics of stem cells
2006; 73 (3): 819-834
View details for Web of Science ID 000245473300010
Seeking consensus: A clarification and defense of altered nuclear transfer
HASTINGS CENTER REPORT
2006; 36 (5): 42-50
View details for PubMedID 17091701
Framing the future: Embryonic stem cells, ethics and the emerging era of developmental biology
2006; 59 (4): 4R-12R
Throughout the 20(th) century, advances in biology were accomplished largely through the study of biochemical parts apart from their place within the whole organism. This reductive and analytic approach, which has culminated in the sequencing of the human genome, has now led us back to the study of living beings. When applied to human biology, this inquiry re-opens the most fundamental questions concerning the moral meaning of developing life. The current conflict over ES (embryonic stem) cell research is just the first in a series of difficult controversies that will require us to clearly and precisely define the boundaries of humanity that we seek to defend. Through a careful consideration of the social, political, and scientific foundations of our current debate, we may discern the terms of a possible resolution that can sustain social consensus while opening avenues for scientific advance. Four such proposals were discussed in a May 2005 publication by the President's Council on Bioethics, entitled "Alternative Sources of Pluripotent Stem Cells." One of these methods, altered nuclear transfer, proposes to use the technology of somatic cell nuclear transfer (SCNT), but with a pre-emptive genetic or epigenetic alteration that precludes the integrated and coordinated organization essential for natural embryogenesis. The moral and scientific dimensions of this proposal are discussed as a way forward for embryonic stem cell research as well as a frame for further studies in developmental biology.
View details for DOI 10.1203/01.pdr.0000205377.04359.3e
View details for Web of Science ID 000236359600002
View details for PubMedID 16549542
- Altered nuclear transfer as a morally acceptable means for the procurement of human embryonic stem cells PERSPECTIVES IN BIOLOGY AND MEDICINE 2005; 48 (2): 211-228
Altered nuclear transfer as a morally acceptable means for the procurement of human embryonic stem cells.
The national Catholic bioethics quarterly
2005; 5 (1): 145-151
View details for PubMedID 15887345
Patenting humans: Clones, chimeras, and biological artifacts
5th International Bioethics Conference
SPRINGER. 2005: 21–29
The momentum of advances in biology is evident in the history of patents on life forms. As we proceed forward with greater understanding and technological control of developmental biology there will be many new and challenging dilemmas related to patenting of human parts and partial trajectories of human development. These dilemmas are already evident in the current conflict over the moral status of the early human embryo. In this essay, recent evidence from embryological studies is considered and the unbroken continuity of organismal development initiated at fertilization is asserted as clear and reasonable grounds for moral standing. Within this frame of analysis, it is proposed that through a technique of Altered Nuclear Transfer, non-organismal entities might be created from which embryonic stem cells could be morally procured. Criteria for patenting of such non-organismal entities are considered.
View details for Web of Science ID 000226839800005
View details for PubMedID 15726996
Altered nuclear transfer - A way forward for embryonic stem cell research
STEM CELL REVIEWS
2005; 1 (4): 293-300
The present conflict over the moral status of the human embryo reflects deep differences in our basic convictions and is unlikely to be resolved through deliberation or debate. While there are currently no federally legislated constraints on the use of private funds for this research, there is a consensus opinion in the scientific community that without NIH support for newly created embryonic stem cell lines, progress in this important realm of research will be severely constrained. A May, 2005, report by the President's Council on Bioethics, "Alternative Sources of Pluripotent Stem Cells," outlines several proposals for obtaining pluripotent stem cells without the destruction of human embryos. One of these methods, Altered Nuclear Transfer, proposes to use the technology of somatic cell nuclear transfer (SCNT), but with a preemptive genetic or epigenetic alteration that precludes the integrated and coordinated organization essential for natural embryogenesis. Drawing on insights from systems biology, the distinction between totipotency (capacity to form a whole organism) and pluripotency (capacity to form all the cell types) is explored. The implications of this distinction are used to discuss the moral arguments for the inviolability of nascent human life and the moral standing of entities with only partial and unorganized developmental potential. Away forward is proposed that may open positive avenues of advance in both stem cell research and a broader arena of research in developmental biology.
View details for Web of Science ID 000240469000004
View details for PubMedID 17142870
Can a morally acceptable way be found to obtain embryonic stem cells?
2004; 34 (27): 429-433
View details for PubMedID 15688547
On the horizon in biotechnology
18th Workshop for Bishops of the United States and Canada
NATL CATHOLIC BIOETHICS CENTER. 2002: 11–29
View details for Web of Science ID 000189196700001
Evolutionary theory and the emergence of moral nature
JOURNAL OF PSYCHOLOGY AND THEOLOGY
2001; 29 (4): 330-339
View details for Web of Science ID 000173123800005